Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of drugs used to treat human immunodeficiency virus (HIV) infection. NRTIs are metabolized into active nucleotide triphosphate derivatives in the body and bind competitively to the HIV reverse transcriptase, preventing the conversion of viral RNA into DNA, thereby inhibiting viral replication.
The global Nucleoside Reverse Transcriptase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Nucleoside Reverse Transcriptase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Nucleoside Reverse Transcriptase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Nucleoside Reverse Transcriptase Inhibitors include GSK, MSD, Mylan Laboratories, Takeda Pharmaceutical, Emcure Pharmaceuticals, LUPIN PHARMS, Aurobindo Pharma, Gilead Sciences, Kainos Medicine, Celltrion, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleoside Reverse Transcriptase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleoside Reverse Transcriptase Inhibitors.
The Nucleoside Reverse Transcriptase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Nucleoside Reverse Transcriptase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleoside Reverse Transcriptase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
GSK
MSD
Mylan Laboratories
Takeda Pharmaceutical
Emcure Pharmaceuticals
LUPIN PHARMS
Aurobindo Pharma
Gilead Sciences
Kainos Medicine
Celltrion
Strides Pharma
Cipla
Vibe Healthcare
Shionogi
ViiV Healthcare
HETERO LABS
Blanver Farmoquimica
Viriom
Apotex
DESANO
Hansoh Pharma
Genuine Biotech
Segment by Type
Tablet
Oral Solution
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nucleoside Reverse Transcriptase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nucleoside Reverse Transcriptase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Nucleoside Reverse Transcriptase Inhibitors Market Overview
1.1 Product Definition
1.2 Nucleoside Reverse Transcriptase Inhibitors by Type
1.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Tablet
1.2.3 Oral Solution
1.3 Nucleoside Reverse Transcriptase Inhibitors by Application
1.3.1 Global Nucleoside Reverse Transcriptase Inhibitors Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Nucleoside Reverse Transcriptase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Nucleoside Reverse Transcriptase Inhibitors Revenue 2019-2030
1.4.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales 2019-2030
1.4.3 Global Nucleoside Reverse Transcriptase Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Nucleoside Reverse Transcriptase Inhibitors Market Competition by Manufacturers
2.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Nucleoside Reverse Transcriptase Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Nucleoside Reverse Transcriptase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nucleoside Reverse Transcriptase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nucleoside Reverse Transcriptase Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Nucleoside Reverse Transcriptase Inhibitors, Date of Enter into This Industry
2.8 Global Nucleoside Reverse Transcriptase Inhibitors Market Competitive Situation and Trends
2.8.1 Global Nucleoside Reverse Transcriptase Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Nucleoside Reverse Transcriptase Inhibitors Players Market Share by Revenue
2.8.3 Global Nucleoside Reverse Transcriptase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nucleoside Reverse Transcriptase Inhibitors Market Scenario by Region
3.1 Global Nucleoside Reverse Transcriptase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Region: 2019-2030
3.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Region: 2019-2024
3.2.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Region: 2025-2030
3.3 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Region: 2025-2030
3.4 North America Nucleoside Reverse Transcriptase Inhibitors Market Facts & Figures by Country
3.4.1 North America Nucleoside Reverse Transcriptase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2030)
3.4.3 North America Nucleoside Reverse Transcriptase Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nucleoside Reverse Transcriptase Inhibitors Market Facts & Figures by Country
3.5.1 Europe Nucleoside Reverse Transcriptase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Nucleoside Reverse Transcriptase Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nucleoside Reverse Transcriptase Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Nucleoside Reverse Transcriptase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Nucleoside Reverse Transcriptase Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific Nucleoside Reverse Transcriptase Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nucleoside Reverse Transcriptase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Nucleoside Reverse Transcriptase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Nucleoside Reverse Transcriptase Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nucleoside Reverse Transcriptase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Nucleoside Reverse Transcriptase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Nucleoside Reverse Transcriptase Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2030)
4.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2024)
4.1.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2025-2030)
4.1.3 Global Nucleoside Reverse Transcriptase Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Nucleoside Reverse Transcriptase Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Nucleoside Reverse Transcriptase Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2030)
5.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2024)
5.1.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2025-2030)
5.1.3 Global Nucleoside Reverse Transcriptase Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Nucleoside Reverse Transcriptase Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Nucleoside Reverse Transcriptase Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 MSD
6.2.1 MSD Company Information
6.2.2 MSD Description and Business Overview
6.2.3 MSD Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 MSD Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.2.5 MSD Recent Developments/Updates
6.3 Mylan Laboratories
6.3.1 Mylan Laboratories Company Information
6.3.2 Mylan Laboratories Description and Business Overview
6.3.3 Mylan Laboratories Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Laboratories Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.3.5 Mylan Laboratories Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Company Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceutical Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Emcure Pharmaceuticals
6.5.1 Emcure Pharmaceuticals Company Information
6.5.2 Emcure Pharmaceuticals Description and Business Overview
6.5.3 Emcure Pharmaceuticals Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Emcure Pharmaceuticals Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.5.5 Emcure Pharmaceuticals Recent Developments/Updates
6.6 LUPIN PHARMS
6.6.1 LUPIN PHARMS Company Information
6.6.2 LUPIN PHARMS Description and Business Overview
6.6.3 LUPIN PHARMS Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 LUPIN PHARMS Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.6.5 LUPIN PHARMS Recent Developments/Updates
6.7 Aurobindo Pharma
6.7.1 Aurobindo Pharma Company Information
6.7.2 Aurobindo Pharma Description and Business Overview
6.7.3 Aurobindo Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Aurobindo Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.7.5 Aurobindo Pharma Recent Developments/Updates
6.8 Gilead Sciences
6.8.1 Gilead Sciences Company Information
6.8.2 Gilead Sciences Description and Business Overview
6.8.3 Gilead Sciences Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gilead Sciences Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.8.5 Gilead Sciences Recent Developments/Updates
6.9 Kainos Medicine
6.9.1 Kainos Medicine Company Information
6.9.2 Kainos Medicine Description and Business Overview
6.9.3 Kainos Medicine Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Kainos Medicine Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.9.5 Kainos Medicine Recent Developments/Updates
6.10 Celltrion
6.10.1 Celltrion Company Information
6.10.2 Celltrion Description and Business Overview
6.10.3 Celltrion Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Celltrion Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.10.5 Celltrion Recent Developments/Updates
6.11 Strides Pharma
6.11.1 Strides Pharma Company Information
6.11.2 Strides Pharma Description and Business Overview
6.11.3 Strides Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Strides Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.11.5 Strides Pharma Recent Developments/Updates
6.12 Cipla
6.12.1 Cipla Company Information
6.12.2 Cipla Description and Business Overview
6.12.3 Cipla Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Cipla Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.12.5 Cipla Recent Developments/Updates
6.13 Vibe Healthcare
6.13.1 Vibe Healthcare Company Information
6.13.2 Vibe Healthcare Description and Business Overview
6.13.3 Vibe Healthcare Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Vibe Healthcare Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.13.5 Vibe Healthcare Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Company Information
6.14.2 Shionogi Description and Business Overview
6.14.3 Shionogi Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Shionogi Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 ViiV Healthcare
6.15.1 ViiV Healthcare Company Information
6.15.2 ViiV Healthcare Description and Business Overview
6.15.3 ViiV Healthcare Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 ViiV Healthcare Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.15.5 ViiV Healthcare Recent Developments/Updates
6.16 HETERO LABS
6.16.1 HETERO LABS Company Information
6.16.2 HETERO LABS Description and Business Overview
6.16.3 HETERO LABS Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.16.4 HETERO LABS Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.16.5 HETERO LABS Recent Developments/Updates
6.17 Blanver Farmoquimica
6.17.1 Blanver Farmoquimica Company Information
6.17.2 Blanver Farmoquimica Description and Business Overview
6.17.3 Blanver Farmoquimica Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Blanver Farmoquimica Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.17.5 Blanver Farmoquimica Recent Developments/Updates
6.18 Viriom
6.18.1 Viriom Company Information
6.18.2 Viriom Description and Business Overview
6.18.3 Viriom Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Viriom Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.18.5 Viriom Recent Developments/Updates
6.19 Apotex
6.19.1 Apotex Company Information
6.19.2 Apotex Description and Business Overview
6.19.3 Apotex Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Apotex Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.19.5 Apotex Recent Developments/Updates
6.20 DESANO
6.20.1 DESANO Company Information
6.20.2 DESANO Description and Business Overview
6.20.3 DESANO Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.20.4 DESANO Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.20.5 DESANO Recent Developments/Updates
6.21 Hansoh Pharma
6.21.1 Hansoh Pharma Company Information
6.21.2 Hansoh Pharma Description and Business Overview
6.21.3 Hansoh Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Hansoh Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.21.5 Hansoh Pharma Recent Developments/Updates
6.22 Genuine Biotech
6.22.1 Genuine Biotech Company Information
6.22.2 Genuine Biotech Description and Business Overview
6.22.3 Genuine Biotech Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Genuine Biotech Nucleoside Reverse Transcriptase Inhibitors Product Portfolio
6.22.5 Genuine Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nucleoside Reverse Transcriptase Inhibitors Industry Chain Analysis
7.2 Nucleoside Reverse Transcriptase Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nucleoside Reverse Transcriptase Inhibitors Production Mode & Process
7.4 Nucleoside Reverse Transcriptase Inhibitors Sales and Marketing
7.4.1 Nucleoside Reverse Transcriptase Inhibitors Sales Channels
7.4.2 Nucleoside Reverse Transcriptase Inhibitors Distributors
7.5 Nucleoside Reverse Transcriptase Inhibitors Customers
8 Nucleoside Reverse Transcriptase Inhibitors Market Dynamics
8.1 Nucleoside Reverse Transcriptase Inhibitors Industry Trends
8.2 Nucleoside Reverse Transcriptase Inhibitors Market Drivers
8.3 Nucleoside Reverse Transcriptase Inhibitors Market Challenges
8.4 Nucleoside Reverse Transcriptase Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
GSK
MSD
Mylan Laboratories
Takeda Pharmaceutical
Emcure Pharmaceuticals
LUPIN PHARMS
Aurobindo Pharma
Gilead Sciences
Kainos Medicine
Celltrion
Strides Pharma
Cipla
Vibe Healthcare
Shionogi
ViiV Healthcare
HETERO LABS
Blanver Farmoquimica
Viriom
Apotex
DESANO
Hansoh Pharma
Genuine Biotech
听
听
*If Applicable.